Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors

Expert Opinion on Biological Therapy

Volumn 11, Issue 11, 2011, Pages 1433-1445

  Di Fede, Gaetana ^a   Bronte, Giuseppe ^a   Rizzo, Sergio ^a   Rolfo Cervetto, Christian ^b   Cocorullo, Gianfranco ^c   Gulotta, Gaspare ^c   Bazan, Viviana ^a   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Clinica Rotger   (Spain)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Anti EGFR; Anti HER2; Anti VEGF; Antibody fragments; Monoclonal antibodies

Indexed keywords

ALPHA INTERFERON; ANTIBODY CONJUGATE; BEVACIZUMAB; CARBOPLATIN; CATUMAXOMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMMUNOGLOBULIN F(AB) FRAGMENT; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TEMOZOLOMIDE; TRASTUZUMAB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL PRACTICE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYBRIDOMA; HYPERTENSION; IMMUNOGENICITY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NOMENCLATURE; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECOMBINANT DNA TECHNOLOGY; REVIEW; SOLID TUMOR; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; NEOPLASM PROTEINS; NEOPLASMS; TREATMENT OUTCOME;

EID: 80053648778     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.594436     Document Type: Review

References (96)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57 (Pubitemid 41486396)
2. Schaedel O, Reiter Y. Antibodies and their fragments as anti-cancer agents. Curr Pharm Des 2006;12:363-78
3. General policies for monoclonal antibodies. Geneva, Switzerland: World Health Organization (WHO) 2009.Available from: http://www. who.int/medicines/ services/inn/Generalpoliciesformonoclonal antibodies2009.pdf [Last accessed 4 June 2011]
4. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
5. Milstein C. With the benefit of hindsight. Immunol Today 2000;21:359-64 (Pubitemid 30612295)
6. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev 2001;1:118-29 (Pubitemid 33741887)
7. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129-34 (Pubitemid 36098274)
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
9. Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 2005;338:627-38
10. Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336-40 (Pubitemid 28144094)
11. Bloch W, Huggel K, Sasaki T, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000;14:2373-6
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76 (Pubitemid 36749215)
13. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400 (Pubitemid 38618122)
14. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9 (Pubitemid 27441066)
15. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7 (Pubitemid 38524883)
16. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21 (Pubitemid 44511625)
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 (Pubitemid 38702844)
18. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44 (Pubitemid 46733080)
19. Kozloff M, Hainswrth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [abstract 3537]. J Clin Oncol 2006;2006:155
20. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20:1842-7
21. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-9 (Pubitemid 46870935)
22. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50 (Pubitemid 44917502)
23. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
24. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904 (Pubitemid 44175140)
25. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
26. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47
27. Robert NJ, Dieras V, Glaspy J. RIBBON-1: randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;abstract 1005
28. Stark Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology; 5-8 May 2005; Neuro-Oncology, Edinburgh; United Kingdom; 2005. p. 369
29. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166-93
30. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40
31. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5
32. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11 (Pubitemid 350296300)
33. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96
34. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92 (Pubitemid 32222155)
35. Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74 (Pubitemid 46207001)
36. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract 2006;3:269-80 (Pubitemid 43731112)
37. Montemurro F, Redana S, Viale G, et al. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clin Breast Cancer 2008;8:436-42
38. Pirvulescu C, Uhlig M, von Minckwitz G. Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression. Breast Care (Basel, Switzerland) 2008;3:364-5
39. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-15 (Pubitemid 46622286)
40. Rayson D, Richel D, Chia S, et al. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008;19:1530-9
41. Slamon DJ, Mackey J, Robert N, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease [abstract 13]. San Antonio Breast Cancer Symposium; 2007. Br Cancer Res Treat 2007;106:112
42. Sledge G, O' Neill A, Thor A, et al. Adjuvant trastuzumab: Long term results of E2198. San Antonio Breast Cancer Symposium; 2006. Br Cancer Res Treat 2006;95(Suppl 1): abstract 2075
43. Joensuu H, Kellokumpu-Lehtinen PL, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20 (Pubitemid 43290919)
44. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10 (Pubitemid 46211358)
45. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45 (Pubitemid 38944402)
46. Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 2004;58:914-26 (Pubitemid 38221151)
47. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
48. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15 (Pubitemid 351325672)
49. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9 (Pubitemid 46625066)
50. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9 (Pubitemid 351171687)
51. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-84 (Pubitemid 28222141)
52. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8 (Pubitemid 46548951)
53. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12
54. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86 (Pubitemid 40590264)
55. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25:3238-45 (Pubitemid 47325607)
56. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-7
57. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-269
58. Committee for Medicinal Products for Human Use Post-authorisation Summary of Positive Opinion for Erbitux. London, UK: European Medicines Agency, 2008. Available from: http://www.emea.europa.eu/pdfs/human/opinion/Erbitux-28040208en. pdf [Last accessed 5 June 2011]
59. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-19
60. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8 (Pubitemid 350106711)
61. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
62. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71
63. Van Cutsem E, Rougier P, Kohne C, et al. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status. The joint ECCO 1534th ESMO Multidisciplinary Congress September 20-24, 2009; Berlin [abstract P-6077]. Eur J Cancer Suppl 2009;7:345
64. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4 ± cetuximab as 1st-line treatment for metastatic colorectal cancer: the OPUS study. The joint ECCO 15-34th ESMO Multidisciplinary Congress September 20-24, 2009; Berlin [abstract 6079]. Eur J Cancer 7(Suppl):S346
65. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78 (Pubitemid 43209104)
66. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54 (Pubitemid 46211507)
67. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
68. Van Cutsem E, Peeters M, Siena S, et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64 (Pubitemid 46797944)
69. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19:92-8
70. Reichert JM. Antibodies to watch in 2010. mAbs 2:84-100
71. Herlyn D, Wettendorff M, Schmoll E, et al. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 1987;84:8055-9 (Pubitemid 17162819)
72. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994;343:1177-83 (Pubitemid 24147551)
73. Hartung G, Hofheinz RD, Dencausse Y, et al. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized Phase III study. Onkologie 2005;28:347-50 (Pubitemid 40827490)
74. Colacchio TA, Niedzwiecki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). ASCO Annual Meeting; 2004: 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(15 Suppl):3522
75. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671-7 (Pubitemid 35232335)
76. Fields AL, Keller A, Schwartzberg L, et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009;27:1941-7
77. Gelmon KA, Fumoleau P, Verma S, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. ASCO Annual Meeting; 2008 May 30-June 3; Chicago. J Clin Oncol 2008;26(20 Suppl):abstract 1026
78. 2+ metastatic breast cancer patients previously treated with trastuzumab. CTRC-AACR San Antonio Breast Cancer Symposium; 2008.San Antonio, Texas: Cancer Research 2008. Abstract 3138. Available at: http://www. posters2view.com/sabcs08/viewp.php?nu=3138
79. Baselga J, Swain SM. CLEOPATRA: a Phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010;10:489-91
80. Langdon SP, Faratian D, Nagumo Y, et al. Pertuzumab for the treatment of ovarian cancer. Expert Opin Biol Ther 2010;10:1113-20
81. Schmitt M, Schmitt A, Reinhardt P, et al. Opsonization with a trifunctional bispecific (alphaCD3 X alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004;25:841-8
82. Ruf P, Gires O, Jager M, et al. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007;97:315-21 (Pubitemid 47196752)
83. Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6 (Pubitemid 30411727)
84. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM X anti-CD3 antibody: a Phase I/II study. Clin Cancer Res 2007;13:3899-905 (Pubitemid 47037597)
85. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-21
86. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res 2003;20:1337-50 (Pubitemid 37164040)
87. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77:1405-12 (Pubitemid 28190739)
88. Albrecht H, Burke PA, Natarajan A, et al. Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. Bioconjug Chem 2004;15:16-26 (Pubitemid 38165976)
89. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005;20:17-29
90. Perisic O, Webb PA, Holliger P, et al. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994;2:1217-26 (Pubitemid 124001320)
91. Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61
92. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9 (Pubitemid 32937367)
93. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52 (Pubitemid 38821812)
94. Sliwkowski MX, Loame JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(4 Suppl 12):60-70 (Pubitemid 29411434)
95. Kimura H, Sakai K, Arao T, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007;98:1275-80 (Pubitemid 46993549)
96. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010;184:512-20